

## HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of primary or secondary myelofibrosis - may be restricted from strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion criteria which are specified by diagnosis

---

**Exclusion Criteria:**

- eligible for allogeneic bone marrow or stem cell transplantation - history of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within the past 6 months - history of chronic liver disease - women who are pregnant or breastfeeding -see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete exclusion criteria which are specified by diagnosis

### Conditions & Interventions

**Conditions:**

Cancer, Rare Diseases

**Keywords:**

Clinics and Surgery Center (CSC), Myelofibrosis

### More Information

**Description:** This study is testing an compound called TP-3654, which is an investigational product being developed for Myelofibrosis.

**Study Contact:** Naveen Premnath - [premn007@umn.edu](mailto:premn007@umn.edu)

**Principal Investigator:** Naveen Premnath

**Phase:** PHASE1

**IRB**

**Number:** STUDY00023042

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.